Bausch Health Companies Inc. (TSE:BHC - Free Report) - Analysts at Zacks Research lowered their Q2 2025 EPS estimates for Bausch Health Companies in a note issued to investors on Wednesday, May 21st. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.37 for the quarter, down from their prior estimate of $1.52. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q3 2025 earnings at $1.47 EPS, Q4 2025 earnings at $1.64 EPS, FY2025 earnings at $5.29 EPS, Q1 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.56 EPS, FY2026 earnings at $5.68 EPS, Q1 2027 earnings at $1.53 EPS and FY2027 earnings at $6.73 EPS.
Bausch Health Companies Stock Down 1.7%
Shares of BHC stock traded down C$0.11 during mid-day trading on Monday, reaching C$6.25. 22,847 shares of the company were exchanged, compared to its average volume of 340,311. The company has a market capitalization of C$1.63 billion, a P/E ratio of -9.15, a P/E/G ratio of 0.21 and a beta of 0.77. The business's 50 day simple moving average is C$7.14 and its 200 day simple moving average is C$9.52. The company has a debt-to-equity ratio of -1,831.94, a quick ratio of 0.58 and a current ratio of 1.19. Bausch Health Companies has a fifty-two week low of C$5.45 and a fifty-two week high of C$13.74.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
